Tozorakimab (Anti-IL-33), OBERON and TITANIA
Symptomatic chronic obstructive pulmonary disease
Sponsor: AstraZeneca
- 2,304Enrollment target
- N/ATrial sites
- N/ACountries
- March 2026Est. completion
- NCT05158387Registry record
About this trial
Anti-IL-33 monoclonal antibody in COPD — the same target Sanofi abandoned with itepekimab, with the opposite result.
Primary endpoints
- Annualised rate of moderate or severe COPD exacerbations
Latest update
September 2026
AstraZeneca reported full Phase 3 results showing tozorakimab produced statistically significant and clinically meaningful reductions in COPD exacerbations across both pivotal trials and across eosinophil levels, described as a first for the anti-IL-33 class. Topline wins were announced on 27 March and 6 May 2026.
SourceTrial information is compiled from public sources and may be out of date. It is not medical advice and is not an offer of enrolment; check the registry entry or speak to a physician before acting on it.